{
    "clinical_study": {
        "@rank": "134409", 
        "arm_group": {
            "arm_group_label": "intraperitoneal chemotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Intraperitoneal chemotherapy with cisplatin at a dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% and doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution with a flow of 30 ml/min and a max upstream pressure of 200 psi."
        }, 
        "brief_summary": {
            "textblock": "This trial aims to assess efficacy and safety of an intraperitoneal, aerosol, high-pressure\n      chemotherapy in women with recurrent ovarian cancer"
        }, 
        "brief_title": "Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This study aims to investigate the therapeutic efficacy of PIPAC using doxorubicin and\n      cisplatin in women with recurrent ovarian cancer and disease progression with peritoneal\n      carcinomatosis. The primary objective of this study is to determine the Clinical Benefit\n      Rate (CBR) according to RECIST criteria   after three cycles of PIPAC with cisplatin and\n      doxorubicin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  at least 2 lines of previous chemotherapy\n\n          -  recurrent ovarian cancer\n\n          -  patient is mobile\n\n          -  informed consent\n\n        Exclusion Criteria:\n\n          -  ileus\n\n          -  necessity of parenteral nutrition"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01809379", 
            "org_study_id": "PIPAC-OV1"
        }, 
        "intervention": {
            "arm_group_label": "intraperitoneal chemotherapy", 
            "description": "intraperitoneal chemotherapy applied as an aerosol and under pressure", 
            "intervention_name": "chemotherapy with doxorubicin and cisplatin", 
            "intervention_type": "Drug", 
            "other_name": "CISPLATIN Teva, Adrimedac"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Doxorubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "ovarian cancer, recurrent, chemotherapy, intraperitoneal", 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "contact": {
                "email": "clemens.tempfer@marienhospital-herne.de", 
                "last_name": "Clemens Tempfer, MD", 
                "phone": "+49 2323 499", 
                "phone_ext": "1801"
            }, 
            "facility": {
                "address": {
                    "city": "Bochum", 
                    "country": "Germany", 
                    "state": "NRW", 
                    "zip": "44623"
                }, 
                "name": "Ruhr University Bochum"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase II Clinical Trial", 
        "other_outcome": {
            "description": "various measures of response to therapy on the clinical, biochemical, and histological level", 
            "measure": "tumor apoptosis assessment, videolaparoscopy assessment of response, CA 125 assessment of response", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "overall_contact": {
            "email": "clemens.tempfer@marienhospital-herne.de", 
            "last_name": "Clemens Tempfer, MD", 
            "phone": "+49 2323 499", 
            "phone_ext": "1801"
        }, 
        "overall_official": {
            "affiliation": "Runr University Bochum", 
            "last_name": "Clemens Tempfer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The clinical benefit rate comprises complete remission, partial remission, and stable disease according to RECIST criteria.", 
            "measure": "Clinical Benefit Rate", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01809379"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ruhr University of Bochum", 
            "investigator_full_name": "Clemens Tempfer", 
            "investigator_title": "Prof. Dr. med. Clemens Tempfer, MBA", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "left heart ejection fraction, neurological status, laparoscopy complications intraoperative, laparoscopy complications postoperative until hospital discharge, re-admission to hospital, death", 
            "measure": "safety", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Ruhr University of Bochum", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ruhr University of Bochum", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}